NPPNY.US Nippon Shinyaku Co Ltd ADR
- Market cap
- USD 1.44B
- P/E
- 7.0x
- P/B
- 0.78x
- ROE
- 10.7%
- Dividend yield
- 3.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is NPPNY.US undervalued?
Graham numberNPPNY.US trades 50.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nippon Shinyaku Co Ltd ADR fundamental analysis
No fundamental analysis for Nippon Shinyaku Co Ltd ADR yet.
Nippon Shinyaku Co Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nippon Shinyaku Co Ltd ADR
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with At…
Full company profileNippon Shinyaku Co Ltd ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nippon Shinyaku Co Ltd ADR annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 98.8B | 101B | 115B | 117B | 122B | 137B | 144B | 148B | 160B | 181B | 197B |
| Gross Profit | 53.9B | 54.5B | 63.8B | 63.5B | 71.9B | 87.3B | 88.2B | 97.0B | 109B | 120B | 127B |
| Operating Income | 15.3B | 17.1B | 20.6B | 21.7B | 26.1B | 32.9B | 30.0B | 31.4B | 36.8B | 35.0B | 40.0B |
| EBITDA | 17.9B | 19.9B | 25.0B | 25.9B | 30.5B | 38.0B | 35.7B | 36.3B | 41.5B | 42.1B | 47.3B |
| Net Income | 11.7B | 13.0B | 16.3B | 16.9B | 19.5B | 25.0B | 22.8B | 25.9B | 32.6B | 31.5B | 31.2B |
| EPS | 44 | 48 | 61 | 63 | 73 | 93 | 85 | 96 | 121 | 117 | 116 |
| Balance Sheet | |||||||||||
| Total Assets | 151B | 158B | 169B | 175B | 197B | 220B | 237B | 263B | 284B | 348B | 338B |
| Total Liabilities | 36.6B | 32.5B | 33.6B | 29.3B | 34.5B | 39.1B | 41.5B | 42.9B | 36.3B | 54.7B | 45.4B |
| Shareholders' Equity | 114B | 125B | 135B | 145B | 162B | 181B | 196B | 220B | 247B | 293B | 292B |
| Cash & Short-term Investments | 39.4B | 32.9B | 42.1B | 47.1B | 60.8B | 65.7B | 71.6B | 68.7B | 55.2B | 79.0B | 73.3B |
| Total Debt | 278M | 8.00M | 5.00M | 7.00M | 2.84B | 2.71B | 2.66B | 2.87B | 2.72B | 2.58B | 3.35B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 18.9B | 6.72B | 15.3B | 12.7B | 21.4B | 21.3B | 26.2B | 16.3B | 36.1B | 28.9B | 25.8B |
| Capital Expenditure | 4.35B | 4.18B | 1.46B | 1.82B | 2.17B | 8.94B | 11.7B | 9.65B | 3.35B | 3.16B | 3.89B |
| Free Cash Flow | 14.6B | 2.54B | 13.9B | 10.9B | 19.2B | 12.4B | 14.4B | 6.64B | 32.8B | 25.7B | 21.9B |
| Ratios | |||||||||||
| ROE | 10.3% | 10.3% | 12.1% | 11.6% | 12.0% | 13.8% | 11.7% | 11.7% | 13.2% | 10.8% | 10.7% |
| ROA | 7.8% | 8.2% | 9.7% | 9.6% | 9.9% | 11.4% | 9.6% | 9.8% | 11.5% | 9.1% | 9.2% |
| Net Profit Margin | 11.9% | 12.8% | 14.2% | 14.5% | 16.0% | 18.2% | 15.8% | 17.4% | 20.3% | 17.4% | 15.9% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nippon Shinyaku Co Ltd ADR dividends
- Dividend yield
- 3.67%
- Forward dividend
- 0.20 USD
- Payout ratio
- 28.1%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 8.86B | 33 | 28.1% |
| 2025 | JPY 8.35B | 31 | 25.6% |
| 2024 | JPY 8.01B | 30 | 31.0% |
| 2023 | JPY 7.81B | 29 | 34.2% |
| 2022 | USD 6.80B | 25 | 27.2% |
| 2021 | USD 6.20B | 23 | 31.7% |
| 2020 | USD 5.65B | 21 | 33.5% |
| 2019 | USD 3.70B | 14 | 22.7% |
| 2018 | JPY 3.77B | 14 | 29.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Nippon Shinyaku Co Ltd ADR
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 270M
- Free float 251M
Nippon Shinyaku Co Ltd ADR company profile
- Company name
- Nippon Shinyaku Co Ltd ADR
- Ticker
- NPPNY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,309
- Fiscal year end
- March
- Address
- 14, Nishinosho-Monguchi-cho, Kyoto, Japan, 601-8550
- Phone
- 81 7 5321 1111
- Website
- nippon-shinyaku.co.jp
About Nippon Shinyaku Co Ltd ADR
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Nippon Shinyaku Co Ltd ADR management
10- Mr. Toru NakaiPresident & Representative Director · born 1971
- Mr. Hideyuki FujiiAccounting & Finance Department Manager
- Manabu BeppuCorporate Officer and Head of R & D Planning and Administration Div.
- Mr. Mitsuharu KoizumiDir. of HR, Gen. Aff., Risk Man., Compliance, Sustain. & Dig.Tran. and Director · born 1966
- Mr. Kazuyuki IwataGM of Sales and Marketing, Head of Sales & Marketing Division and Director · born 1966
- Yoko NakanishiCorporate Officer & Department Manager of Human Resources Dept.
- Mr. Takanori EdamitsuMD of Business Management & Director · born 1963
- Mr. Hitoshi IshizawaGM of Functional Food, Head of Functional Food Division & Director · born 1961
- Hayato WadaCorporate Officer & Department Manager of Kansai Business Office
- Masaya TodaHead of Licensing & Alliance Division and Corporate Officer